Results 41 to 50 of about 11,160 (199)
Anti-Cyclic Citrullinated Peptide Antibodies in Rheumatoid Arthritis and Behcet's Disease
Rheumatoid arthritis (RA) is associated with progressive joint destruction and disability. Early diagnosis of RA is important, since early and aggressive treatments lead to a better outcome. Circulating autoantibodies are a serological hallmark of systemic rheumatic diseases.
Koca, Suleyman Serdar +4 more
openaire +3 more sources
Background Positive anticyclic citrullinated peptide (anti-CCP+) is associated with bone loss in patients with rheumatoid arthritis (RA). However, whether overall positivity or specific levels of anti-CCP are associated with prevalent fracture or a 10 ...
Tien-Tsai Cheng +9 more
doaj +1 more source
Patients improve, patterns persist: longitudinal stability of RA joint involvement patterns
Objective Rheumatoid arthritis is a heterogeneous disease. Data‐driven approaches, from synovial histology to joint involvement patterns (JIPs), have sought to define clinically meaningful subgroups. Whether these subgroups represent stable phenotypes or transient disease states remains unclear.
Tjardo Maarseveen +24 more
wiley +1 more source
Objective We examined associations of post‐traumatic stress disorder (PTSD) and other mental health disorders (OMH) with rheumatoid arthritis (RA), accounting for effects of smoking. Methods We conducted a matched case‐control study, identifying incident RA cases and controls using national Veteran Health Administration data (2006‐2019).
Kelsey Coziahr +15 more
wiley +1 more source
Diagnostic Utility of AxSYM Anti-Cyclic Citrullinated Peptide Antibody Assay
The presence of rheumatoid factor (RF) is one of the classification criteria of the American College of Rheumatology (ACR) for rheumatoid arthritis (RA), but it has a limitation of low specificity. We compared the diagnostic utility of anti-cyclic citrullinated peptide (CCP) antibodies analyzed by an automated immunoassay system with that measured by a
Kyung-Eun, Kim +6 more
openaire +2 more sources
The diagnostic value of anti-cyclic citrullinated peptide antibodies, adenosine deaminase activity and other potential biomarkers for predicting and monitoring rheumatoid arthritis [PDF]
The aim of this study was to investigate the presence of anti-cyclic citrullinated peptide antibodies (anti- CCP2) in RA and non-RA patients and to evaluate the combination of these auto-antibodies with some other markers such as RF and CRP.
Mehanović-Nikolić Jasminka +6 more
doaj
Early Retinal UCHL1 Dysregulation Coupled With Synaptic Loss Reflects Alzheimer's Disease Severity
This study identifies synapse‐enriched deubiquitinase UCHL1 as an early Aβ‐responsive regulator of retinal synaptopathy in Alzheimer's disease. Retinal UCHL1 loss accompanies excitatory synapse degeneration, p75NTR activation, and neuroinflammation, and predicts Braak stage and cognitive decline. Aβ42 fibrils trigger synaptic and UCHL1 depletion before
Altan Rentsendorj +25 more
wiley +1 more source
Objective Interstitial lung disease (ILD) is an important extra‐articular manifestation of rheumatoid arthritis (RA) associated with high mortality and morbidity. Lung ultrasonography (LUS) has recently emerged as a possible screening tool. We assessed the role of LUS in monitoring radiologic progression and the development of new interstitial lung ...
Marie Vermant +15 more
wiley +1 more source
Development of synthetic anti‐cyclic citrullinated peptide antibody and its arthritogenic role [PDF]
This study was undertaken to develop a novel anti‐citrullinated peptide antibody (ACPA) and to investigate its arthritogenicity in a collagen‐induced arthritis (CIA) model. The novel ACPA, 12G1, was developed by injecting cyclic citrullinated antigen in mice and subsequently hybridizing the B cells producing citrullinated peptide‐specific antibodies ...
Kim, Youngkyun +6 more
openaire +3 more sources
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis +22 more
wiley +1 more source

